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Abstract
Colibacillosis is one of the leading causes of disease-related economie loss in the poultry sector. 
Fluoroquinolones are frequently used antimicrobials for the treatment of APEC infections in Europe 
and Asia. However, rapid development and selection of resistance to this class of antimicrobial drugs 
is a significant problem. The objective was to investigate the occurrence of antimicrobial resistance 
against enrofloxacin in APEC strains in Flanders by determining the minimum inhibitory 
concentrations (MIG) and the mutant prevention concentrations (MPC) and by characterizing 
resistance genes through PCR, gel electrophoresis and gene sequencing. 126 APEC strains from 
broilers with clinical colibacillosis were obtained via Animal Flealth Care Flanders (DGZ) and 
Sciensano (November - June 2018). Slide agglutination was used to test for 01, 02 and O78 antigens. 
The MIC was determined using a commercial gradiënt strip test (Liofilchem s.r.L, Roseto degli 
Abruzzi, Italy). The MPC was determined through the agar dilution method on the clinically 
susceptible (MIC < 0.25 pg/mL) and the clinically intermediate (0.5 pg/mL < MIC < 1 pg/mL) strains. 
Ninety-six of the 126 strains were serotyped so far and the MIC of these strains was determined. O78 
was the most prevalent serotype (17%). The majority of the strains (69%) could not be identified. 
Fourty-three percent of the strains were non-wild type (ECOFF: 0.125 Pg/mL), 23% were clinically 
intermediate and 11% were clinically resistant (MIC > 2 pg/ml). The MPC values of the clinically 
susceptible strains ranged from 0.25 pg/ml to 2 pg/mL. Some strains with low MIC values (e.g. 0.016 
pg/mL) had rather high MPC values (e.g. ipg/ml), thus portraying a large mutant selection window 
(MSW). The MPC values of the clinically intermediate strains ranged from 1 pg/ml to 32 pg/ml. The 
remainder of the strains (0=30) will be serotyped and MIC and MPC values will be determined. From 
all the non-wild type strains, the presence of plasmid-associated resistance genes (qnrS, A, B) and 
the sequence of chromosomal resistance genes (gyrA, parC) will be evaluated as wel!. These results 
will be presented at the conference. Acknowledgements: The authors would like to thank Sciensano 
for the supply of the APEC strains. This research is supported by the Special Research Fund of Chent 
University grant number BOF17/STA/014.
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